Cater for patient support programs · From enrolment to the next dose

From enrolment to ongoing support

Enrol on a phone. Patients give consent and complete enrolment through a text link.
Prepare for treatment. Book injection training or a first-dose appointment, with refill and visit reminders.
Stay in touch. Patients reach nurses and case managers through secure messages and video. Conversations enter the case-management system.
Review the program. The manufacturer receives aggregate reports on enrolment, time to first dose and completed check-ins.

Patient support and safety reporting

Interactive product preview

Solvara Support Fictional

Enrol as a patient, then follow a flagged message through the program team’s review.

Try Cater in your browser

Explore Cater with a fictional care team and patients. Your progress is saved on this device.

Try a patient support program

Solvara SupportStep 1 of 2
Before you join
Your doctor has prescribed your treatment. The program helps you start it and stay in touch with a nurse. It’s free, and funded by Arvenna Pharma (fictional).
What we collect
Your name, date of birth, contact details and language, your appointments, what you tell the program team, and the clinic that prescribed your treatment.
Who sees it
The program’s nurses and coordinators. Arvenna Pharma sees only totals, never your name, your messages or your doctor.
If you mention a side effect
The program team must pass it to Arvenna Pharma’s drug safety team, as Canadian rules require, with only what they need to assess it.
Stopping
Leave at any time in Profile, or call (416) 555-0137. Your care with your doctor doesn’t change.
I agree to join Solvara SupportText me remindersOptional. You can change this later.
Agree and continue
Solvara Support
Book injection training
Your first dose, with a program nurse · about 45 minutes
At homeAt a clinic
Wed14FullThu152 timesFri163 timesMon193 times
Thursday, October 15
10:00 a.m.2:30 p.m.
No charge. The program covers this visit.
At your home in Toronto. The nurse brings what’s needed.
Book Thursday at 10:00 a.m.
You can change or cancel up to 24 hours before.
Program team
Thu, Oct 15
Grace Liu, program nurse · 4:10 p.m.
It was good to meet you today, Daniel. Message me any time if you have questions about your injections.
Wed, Oct 21
You · 9:14 a.m.
It went fine, thanks. Since Tuesday there’s a red, itchy rash where I injected. Is that normal?
Automatic reply
Thanks, Daniel. A program nurse will reply today; nurses answer from 8 a.m. to 8 p.m. Eastern. If you have trouble breathing, or swelling of your face, lips or throat, call 911.
Message the program teamSend
In an emergency, call 911.
Solvara SupportSolvara SupportGLGrace LiuProgram nurse
Patient review
Daniel Brennan
Enrolled Tue, Oct 13 · consent on file · first dose Thu, Oct 15
Message from Daniel
Wed, Oct 21, 9:14 a.m.
“It went fine, thanks. Since Tuesday there’s a red, itchy rash where I injected. Is that normal?”
Automatic check · 9:14 a.m.
Possible side effect: “a red, itchy rash where I injected”
Every message, form and call note is checked against the program’s examples, tested before launch and after each change. It’s a second check. You decide what it is. Examples set by the program’s medical lead and Arvenna Pharma drug safety.
Your decision
Your decisionReport it as a possible side effectSend the manufacturer’s form to drug safety within one business dayIt isn’t a side effectRecord why. The flag and your reason stay on the record.
You opened Daniel’s case at 9:14 a.m. Every view is logged.
Solvara SupportSolvara SupportGLGrace LiuProgram nurse
Patient review
Daniel Brennan
Enrolled Tue, Oct 13 · consent on file · first dose Thu, Oct 15
Message from Daniel
Wed, Oct 21, 9:14 a.m.
“It went fine, thanks. Since Tuesday there’s a red, itchy rash where I injected. Is that normal?”
Automatic check · 9:14 a.m.
Possible side effect: “a red, itchy rash where I injected”
Every message, form and call note is checked against the program’s examples, tested before launch and after each change. It’s a second check. You decide what it is. Examples set by the program’s medical lead and Arvenna Pharma drug safety.
Your decision
Your decisionReport it as a possible side effectSend the manufacturer’s form to drug safety within one business dayIt isn’t a side effectRecord why. The flag and your reason stay on the record.
Side-effect report
Arvenna Pharma’s own form, version 3
Reported by
Grace Liu, program nurse
Aware since
Wednesday, October 21, 2026, 9:14 a.m.
About the patient
Initials D.B. · 42. No contact details on the form.
Treatment
The program’s treatment; first dose Thu, Oct 15
What happened
Red, itchy rash at the injection site since Tuesday, October 20. Reported by message on October 21.
Drug safety decides what is reportable to Health Canada. The program sends what it was told.
SimulatedDue by end of day Thu, Oct 22 · one business day
To: Arvenna Pharma drug safety
Sent at 10:02 a.m., on time
Reference AE-2026-0418. Drug safety confirmed receipt.
The record
9:14 a.m.Message received from Daniel Brennan
9:14 a.m.Possible side effect flagged by the automatic check
9:14 a.m.Reviewed by Grace Liu, program nurse: possible side effect
10:02 a.m.Report sent by Grace Liu to Arvenna Pharma drug safety (simulated), AE-2026-0418
10:02 a.m.Within one business day: due Thu, Oct 22. On time.
10:05 a.m.Reply sent by Grace Liu, program nurse
Kept for reconciliation with the drug safety database.
Reply sent at 10:05 a.m. Daniel gets a text saying there’s a new message, with no details in it.
You opened Daniel’s case at 10:05 a.m. Every view is logged.
Solvara SupportProgram reportAPArvenna Pharma (fictional)Read only · patient services
Program-level counts
October 2026, to date
Totals only. This view never shows a name, a message or a prescriber. Counts under 5 show as “fewer than 5”, here and in exports.
Enrolled
38
of 52 patients referred this month
Enrolment to first dose
6 days
median, across 31 patients with a first dose
Check-ins completed
112
of 140 check-ins sent
Enrolled, by province
Province Enrolled
Ontario 24
Quebec 9
British Columbia fewer than 5
Atlantic provinces fewer than 5
All provinces 38
About this data
Counted from the program’s own records each night; a patient appears in a total only after they consent.
Side-effect reports go to drug safety directly, on its own form, not through this view.
Nothing here says which doctors prescribe, and sales teams have no access.
Synthetic program data for this preview.

Province	Enrolled
Ontario	24
Quebec	9
British Columbia	fewer than 5
Atlantic provinces	fewer than 5
All provinces	38

Fictional program, therapy and patient. Safety reporting is simulated.

Side-effect reporting in the program workflow

Staff review patient messages and forms, with software flags providing a second check for possible side effects. We test the flags against your program’s examples before launch and after changes.

Staff report on the manufacturer’s form within the agreed time. Drug safety determines what is reportable.

The optional AI assistant uses manufacturer-approved content, identifies itself as AI and hands over to program staff.

The program’s name and software

The app, website and messages carry the program’s name and identify the funding company. Patient records stay with the provider in Canada. The manufacturer receives aggregate reports.

The manufacturer or provider holding the contract owns the custom software.

Working with your program team

Approved content.

Forms, messages and contact workflows use your approved content. Your team reviews each change before release.

Case management.

We build the interface with the provider’s technology team, agreeing which enrolment details, appointments and conversations enter its patient records. Staff use organizational sign-in.

Multilingual materials.

English and French screens and content are included, with clinical translations following your approval process. Add the languages your patients need.

Program support.

Nurses and reimbursement specialists answer care and coverage questions. Add 24/7 human phone and chat support for app setup, sign-in and navigation.

caterapp.ca/for-pharma#reviewers

For drug safety, privacy and quality

Safety reporting. The agreement sets reporting routes and timing. Flags and reports are logged for reconciliation with the safety database.
Privacy. The provider holds the records, hosted in Canada. Cater works under a processing agreement and supports your privacy assessment, including Law 25 for Quebec patients. Program data is not used for model training.
Patient information. A privacy centre under the program’s name explains how patient information is used. We maintain it for your approval.
Program scope. Support starts after prescribing. The app does not promote the therapy or reward prescribers.
Quality and procurement. Each change records its request, approval and release. We supply audit materials to the manufacturer’s and provider’s review teams. The contract can sit with the manufacturer or provider.

Privacy and security documents Gap the document is to come

Cost and next steps

Each program has a launch fee and an annual licence. Gap the range most programs fall in, for the launch fee and for the annual licence The quote covers program configuration, case-management connections, documentation and ongoing maintenance.

Tell us about your program. We’ll involve the manufacturer and provider in the scope, with a confidentiality agreement if needed.

Who we are

Support patients from enrolment to the next dose.